Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer at risk of relapse have been revised. It is anticipated that the appraisal will begin in early-August 2023 when we will write to you about how you can get involved.